What are the recommended procedures for managing portal hypertension and their associated adverse effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

TIPS Procedure Adverse Effects in Portal Hypertension

The most critical adverse effect of TIPS is hepatic encephalopathy, which affects approximately one-third of patients, while acute procedural complications (bleeding, infection, heart/liver/kidney failure, vascular/bile duct injury) occur in less than 5% of cases 1.

Acute Procedural Complications (<5% incidence)

The immediate risks of TIPS placement include 1:

  • Bleeding - from vascular puncture or liver capsule injury
  • Infection - particularly relevant in PSC patients with dilated bile ducts where TIPS passage through infected ducts poses enhanced infection risk 2
  • Cardiac complications - heart failure from acute volume shifts
  • Hepatic decompensation - acute liver failure in patients with marginal hepatic reserve
  • Renal failure - acute kidney injury from contrast or hemodynamic changes
  • Vascular injury - damage to hepatic vessels, portal vein, or IVC
  • Bile duct injury - particularly in patients with abnormal biliary anatomy
  • Fever - post-procedural inflammatory response

Critical Pitfall in PSC Patients

TIPS may be contraindicated in PSC patients with dilated intrahepatic ducts in the TIPS tract due to significantly increased infection risk from passage through infected bile ducts 2.

Long-Term Complications

Hepatic Encephalopathy (Most Common - 33% of patients)

Hepatic encephalopathy is the dominant long-term complication, occurring in one-third of TIPS patients 1. This results from:

  • Shunting of ammonia and other neurotoxins directly into systemic circulation
  • Bypassing hepatic detoxification mechanisms
  • Progressive liver dysfunction

Clinical presentation ranges from:

  • Mild confusion and drowsiness
  • Progressive disorientation
  • Coma in severe cases
  • Potential mortality if untreated

Management approach 1:

  • Most cases respond to standard medical therapy (lactulose, rifaximin)
  • Simple supportive measures often sufficient
  • Refractory cases may require TIPS reduction or occlusion
  • Risk can be mitigated by reducing stent diameter during initial placement

TIPS Dysfunction and Stenosis

Modern PTFE-covered stents have dramatically reduced stenosis rates compared to bare metal stents and should be used exclusively 1.

Surveillance protocol 1:

  • Doppler ultrasound at 1 week post-procedure in prothrombotic conditions (e.g., Budd-Chiari syndrome)
  • Doppler ultrasound at 6-12 month intervals for routine patients
  • 6-month intervals for patients undergoing HCC surveillance
  • No routine venography indicated except in prothrombotic conditions

Risk Mitigation Strategies

Pre-Procedural Assessment

Mandatory preparation to minimize complications 1:

  1. Cross-sectional imaging - evaluate liver and vascular anatomy
  2. Laboratory assessment:
    • Liver function tests
    • Kidney function tests
    • Coagulation studies (use thromboelastography rather than INR, which is unreliable in liver disease) 1
  3. Cardiac evaluation - assess for heart failure risk
  4. Nutritional assessment - malnutrition increases encephalopathy risk
  5. Encephalopathy risk stratification - identify high-risk patients

Procedural Modifications

To reduce hepatic encephalopathy risk 1:

  • Use smaller diameter stents in high-risk patients
  • Target portal pressure gradient reduction to <12 mmHg or ≥20% reduction from baseline for variceal bleeding 1
  • Balance efficacy against encephalopathy risk for non-bleeding indications

Patient Selection Considerations

TIPS should NOT be performed in 1:

  • Patients with stage 4/5 chronic kidney disease (elective TIPS contraindicated)
  • Very severe liver disease (Child-Pugh C with MELD >14) - unlikely to tolerate procedure
  • Active uncontrolled infection
  • Severe right heart failure
  • PSC with dilated intrahepatic ducts in TIPS tract 2

Multidisciplinary discussion mandatory 1, 3:

  • All elective TIPS cases require hepatology and interventional radiology review
  • Additional specialty consultation (cardiology, nephrology, transplant surgery) on case-by-case basis

Special Populations

PSC-Specific Considerations

Portal hypertension in PSC may occur with F2-F3 fibrosis (non-cirrhotic portal hypertension) due to pre-sinusoidal block from ductular proliferation and portal fibrosis 2. This explains why:

  • HVPG may underestimate portal hypertension severity
  • Varices can occur with HVPG <10 mmHg (unlike alcoholic/viral cirrhosis)
  • Enhanced infection risk exists with biliary dilation

Anesthesia Requirements

General anesthesia or deep sedation with propofol is recommended for all TIPS procedures 1. Procedure duration is approximately 90-120 minutes in uncomplicated cases 1.

References

3
Guideline

easl clinical practice guidelines on tips.

Journal of Hepatology, 2025

Related Questions

Does portal hypertension contribute to systemic arterial hypertension or resistant hypertension?
What are the most common causes of portal hypertension in children and how do they typically present?
What is the appropriate management of a bloody paracentesis in a patient with portal hypertension?
In a 35-year-old patient with chronic liver disease and portal hypertension, a splenectomy performed five years ago, small esophageal varices, and a history of recurrent altered sensorium, now presenting with grade 4 hepatic encephalopathy, what is the appropriate management?
In a patient with non‑cirrhotic portal hypertension who has had an esophageal variceal bleed and also has portal vein thrombosis, should a non‑selective beta‑blocker be used?
In a patient with an estimated glomerular filtration rate of 45 mL/min/1.73 m², is anemia expected?
Which organism is most likely responsible for postoperative infections caused by an autoclave malfunction that limited sterilization temperature to 100 °C?
What is the recommended treatment for primary plasma cell leukemia presenting with renal failure?
What is the appropriate dose of griseofulvin for a 12-year-old child weighing 40 kg with tinea corporis of the face?
Does cyclophosphamide have a role in the treatment of primary plasma‑cell leukemia presenting with renal failure?
Does degarelix have neurological side effects or cause neurological deterioration?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.